All Stories

  1. Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial

    Article • Clinical Microbiology and Infection, August 2023, Elsevier

    Dr Christian Herzog

  2. Immune memory persistence is well documented for hepatitis A vaccines

    Article • Vaccine, August 2021, Elsevier

    Dr Christian Herzog

  3. Clinical, serological and epidemiological features of hepatitis A in León, Nicaragua

    Article • PeerJ, June 2021, PeerJ

    Dr Christian Herzog

  4. Immunological and epidemiological long-term effects of hepatitis A vaccination

    Article • Human Vaccines & Immunotherapeutics, December 2020, Taylor & Francis

    Dr Christian Herzog

  5. Hepatitis A vaccination in immunocompromised patients – the need for individualized vaccination strategies and correct methodology

    Article • Travel Medicine and Infectious Disease, November 2019, Elsevier

    Dr Christian Herzog

  6. Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases—a prospective multi-centre cohort study

    Article • Rheumatology, March 2019, Oxford University Press (OUP)

    Dr Christian Herzog

  7. Serologic differential diagnosis of hepatitis A virus (HAV) infected and vaccinated individuals: How long persist antibodies to non-structural HAV proteins?

    Article • Vaccine, June 2018, Elsevier

    Dr Christian Herzog

  8. An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression – A prospective, open-label, multi-center study

    Article • Travel Medicine and Infectious Disease, January 2018, Elsevier

    Dr Christian Herzog

  9. Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response

    Article • The Journal of Infectious Diseases, September 2016, Oxford University Press (OUP)

    Dr Christian Herzog

  10. Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR

    Article • Travel Medicine and Infectious Disease, July 2016, Elsevier

    Dr Christian Herzog

  11. Changing from whole-cell to acellular pertussis vaccines would trade superior tolerability for inferior protection

    Article • Expert Review of Vaccines, June 2015, Taylor & Francis

    Dr Christian Herzog

  12. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study

    Article • Travel Medicine and Infectious Disease, March 2014, Elsevier

    Dr Christian Herzog

  13. Decreasing Risk of Hepatitis A Infection in León, Nicaragua: Evidence from Cross-Sectional and Longitudinal Seroepidemiology Studies

    Article • PLoS ONE, February 2014, PLOS

    Dr Christian Herzog

  14. Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature

    Article • Expert Review of Vaccines, February 2014, Taylor & Francis

    Dr Christian Herzog

  15. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae

    Article • Vaccine, January 2014, Elsevier

    Dr Christian Herzog

  16. Kinetics of maternally acquired anti-hepatitis A antibodies: Prediction of waning based on maternal or cord blood antibody levels

    Article • Vaccine, March 2013, Elsevier

    Dr Christian Herzog

  17. Surveying adverse event rates: lessons from a virosomal hepatitis A vaccine

    Article • Expert Review of Vaccines, April 2012, Taylor & Francis

    Dr Christian Herzog

  18. The phylogeny of yellow fever virus 17D vaccines

    Article • Vaccine, February 2012, Elsevier

    Dr Christian Herzog, Professor Matthias Niedrig

  19. Real-life versus package insert: A post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers

    Article • Vaccine, July 2011, Elsevier

    Dr Christian Herzog

  20. Successful Memory Response following a Booster Dose with a Virosome-Formulated Hepatitis A Vaccine Delayed Up to 11 Years

    Article • Clinical and Vaccine Immunology, March 2011, ASM Journals

    Dr Christian Herzog

  21. Immunogenicity and reactogenicity of a combined fully liquid DTPw–HepB–Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine

    Article • International Journal of Infectious Diseases, January 2011, Elsevier

    Dr Christian Herzog

  22. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine

    Article • Journal of Medical Virology, September 2010, Wiley

    Dr Christian Herzog

  23. A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador

    Article • Revista Panamericana de Salud Pública, February 2010, FapUNIFESP (SciELO)

    Dr Christian Herzog

  24. Virosomal Hepatitis A Vaccine: Comparing Intradermal and Subcutaneous With Intramuscular Administration

    Article • Journal of Travel Medicine, November 2009, Oxford University Press (OUP)

    Dr Christian Herzog

  25. Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine

    Article • Vaccine, July 2009, Elsevier

    Dr Christian Herzog

  26. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration

    Article • Vaccine, June 2009, Elsevier

    Dr Christian Herzog

  27. Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees

    Article • Vaccine, January 2009, Elsevier

    Dr Christian Herzog

  28. Concomitant Administration of a Virosome-Adjuvanted Hepatitis A Vaccine With Routine Childhood Vaccines at Age Twelve to Fifteen Months: A Randomized Controlled Trial

    Article • The Pediatric Infectious Disease Journal, September 2007, Wolters Kluwer Health

    Dr Christian Herzog

  29. Immunogenicity and Safety of a Pediatric Dose of a Virosome-Adjuvanted Hepatitis A Vaccine

    Article • The Pediatric Infectious Disease Journal, August 2007, Wolters Kluwer Health

    Dr Christian Herzog

  30. Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers

    Article • Travel Medicine and Infectious Disease, December 2006, Elsevier

    Dr Christian Herzog

  31. Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (Epaxal ® ) in the Elderly

    Article • Journal of Travel Medicine, March 2006, Oxford University Press (OUP)

    Dr Christian Herzog

  32. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria–tetanus–pertussis vaccine (DTP-Hib), in Indonesian infants

    Article • Vaccine, March 2006, Elsevier

    Dr Christian Herzog

  33. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers’ diarrhoea in a randomised, double-blind, placebo-controlled study

    Article • Vaccine, October 2005, Elsevier

    Dr Christian Herzog

  34. Unique Characteristics of the Intestinal Immune System as an Inductive Site after Antigen Reencounter

    Article • The Journal of Infectious Diseases, January 2005, Oxford University Press (OUP)

    Dr Christian Herzog

  35. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch

    Article • Vaccine, January 2005, Elsevier

    Dr Christian Herzog

  36. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine

    Article • Vaccine, October 2004, Elsevier

    Dr Christian Herzog, Rob Lambkin-Williams

  37. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children

    Article • The Pediatric Infectious Disease Journal, April 2004, Wolters Kluwer Health

    Dr Christian Herzog

  38. Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine

    Article • Clinical Infectious Diseases, November 2003, Oxford University Press (OUP)

    Dr Christian Herzog

  39. Efficacy of Virosome Hepatitis A Vaccine in Young Children in Nicaragua: Randomized Placebo‐Controlled Trial

    Article • The Journal of Infectious Diseases, September 2003, Oxford University Press (OUP)

    Dr Christian Herzog

  40. Virosome influenza vaccine in children

    Article • Vaccine, December 2002, Elsevier

    Dr Christian Herzog

  41. Efficacy of Intranasal Virosomal Influenza Vaccine in the Prevention of Recurrent Acute Otitis Media in Children

    Article • Clinical Infectious Diseases, July 2002, Oxford University Press (OUP)

    Dr Christian Herzog

  42. Intranasal influenza vaccine: protective efficacy in children and adults

    Article • International Congress Series, October 2001, Elsevier

    Dr Christian Herzog

  43. Detection of antibodies to HAV 3C proteinase in experimentally infected chimpanzees and in naturally infected children

    Article • Vaccine, April 2001, Elsevier

    Dr Christian Herzog

  44. Local and systemic immune responses to combined Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunization and reimmunization

    Article • Vaccine, July 2000, Elsevier

    Dr Christian Herzog

  45. Safety and Immunogenicity of Intranasally Administered Inactivated Trivalent Virosome‐Formulated Influenza Vaccine Containing Escherichia coli Heat‐Labile Toxin as a Mucosal Adjuvant

    Article • The Journal of Infectious Diseases, March 2000, Oxford University Press (OUP)

    Dr Christian Herzog

  46. Immune Response to Rabies Booster Vaccination in Subjects Who Had Postexposure Treatment More Than 5 Years Previously

    Article • Journal of Travel Medicine, June 1999, Oxford University Press (OUP)

    Dr Christian Herzog

  47. Compatible Concurrent Administration of Yellow Fever 17D Vaccine with Oral, Live, Attenuated Cholera CVD103‐HgR and Typhoid Ty21a Vaccines

    Article • The Journal of Infectious Diseases, February 1999, Oxford University Press (OUP)

    Dr Christian Herzog

  48. Compatible Concurrent Administration of Yellow Fever 17D Vaccine with Oral, Live, Attenuated Cholera CVD103-HgR and Typhoid Ty21a Vaccines

    Article • The Journal of Infectious Diseases, February 1999, Oxford University Press (OUP)

    Dr Christian Herzog

  49. Asylsuchende und Fl�chtlinge in der haus�rztlichen Praxis: Probleme und Entwicklungsm�glichkeiten

    Article • Sozial- und Präventivmedizin, January 1998, Springer Science + Business Media

    Dr Christian Herzog

  50. Live oral cholera vaccine

    Article • The Lancet, June 1997, Elsevier

    Dr Christian Herzog

  51. Safety and Immunogenicity of Live Oral Cholera and Typhoid Vaccines Administered Alone or in Combination with Antimalarial Drugs, Oral Polio Vaccine, or Yellow Fever Vaccine

    Article • The Journal of Infectious Diseases, April 1997, Oxford University Press (OUP)

    Dr Christian Herzog

  52. Mumpsepidemiologie ? weltweit

    Article • Sozial- und Präventivmedizin, March 1995, Springer Science + Business Media

    Dr Christian Herzog

  53. Inactivated virosome hepatitis A vaccine

    Article • The Lancet, May 1994, Elsevier

    Dr Christian Herzog

  54. Neue Bücher

    Article • Sozial- und Präventivmedizin, January 1988, Springer Science + Business Media

    Dr Christian Herzog

  55. Neue Bücher

    Article • Sozial- und Präventivmedizin, January 1987, Springer Science + Business Media

    Dr Christian Herzog

  56. SEROLOGICAL DIAGNOSIS OF STAPHYLOCOCCAL BACTERAEMIA

    Article • The Lancet, November 1986, Elsevier

    Dr Christian Herzog

  57. Zur Eliminierung von Masern, Mumps und Röteln in der Schweiz

    Article • Sozial- und Präventivmedizin, November 1986, Springer Science + Business Media

    Dr Christian Herzog

  58. Neue Bücher

    Article • Sozial- und Präventivmedizin, November 1986, Springer Science + Business Media

    Dr Christian Herzog

  59. Intranasal interferon (rIFN-αA, Ro 22-8181) for contact prophylaxis against common cold: A randomized, double-blind and placebo-controlled field study

    Article • Antiviral Research, May 1986, Elsevier

    Dr Christian Herzog

  60. Neue Bücher

    Article • Sozial- und Präventivmedizin, November 1985, Springer Science + Business Media

    Dr Christian Herzog

  61. TUBERCULIN SENSITIVITY TESTING

    Article • The Lancet, November 1982, Elsevier

    Dr Christian Herzog

  62. DETECTING TUBERCULIN SENSITIVITY

    Article • The Lancet, October 1982, Elsevier

    Dr Christian Herzog

  63. Schutzimpfungen: Stand 1982

    Article • Sozial- und Präventivmedizin, September 1982, Springer Science + Business Media

    Dr Christian Herzog

  64. REASON FOR VARIABLE RESPONSE TO TUBERCULIN TINE TEST

    Article • The Lancet, August 1981, Elsevier

    Dr Christian Herzog

  65. Berichtigung

    Article • Infection, September 1977, Springer Science + Business Media

    Dr Christian Herzog

  66. Drug treatment of typhoid fever.

    Article • BMJ, October 1976, BMJ

    Dr Christian Herzog

  67. Chemotherapy of typhoid fever: A review of literature

    Article • Infection, September 1976, Springer Science + Business Media

    Dr Christian Herzog

  68. CHLORAMPHENICOL-RESISTANT SALMONELLA TYPHI

    Article • The Lancet, December 1973, Elsevier

    Dr Christian Herzog